MapLight Therapeutics to Participate in Upcoming Investor Conference
MapLight Therapeutics (MPLT) will participate in the Jefferies Global Healthcare Conference in London on November 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MapLight Therapeutics (MPLT) will participate in the Jefferies Global Healthcare Conference in London on November 18, 2026. Management will present and host one-on-one meetings. Where available, live webcasts and archived recordings will be posted on the company’s investor website under Events & Presentations.
Details
Market Reaction – MPLT
On Nov 10, the first trading day after this news, the latest delayed price for MPLT is 4.81% above the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $7.63.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
Event: 2026 Jefferies Global Healthcare Conference (London, UK)
Date: Wednesday, November 18th
Format: Presenting and hosting 1x1 meetings
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.
For investor inquiries: investors@maplightrx.com
For media inquiries: media@maplightrx.com
